Finlay A. McAlister, MD, MSc; Justin A. Ezekowitz, MB, BCh, MSc; Natasha Wiebe, Mmath; Brian Rowe, MD, MSc; Carol Spooner, MSc; Ellen Crumley, MLIS; Lisa Hartling, MSc; Terry Klassen, MD, MSc; William Abraham, MD
McAlister FA, Ezekowitz JA, Wiebe N, Rowe B, Spooner C, Crumley E, et al. Systematic Review: Cardiac Resynchronization in Patients with Symptomatic Heart Failure. Ann Intern Med. 2004;141:381-390. doi: 10.7326/0003-4819-141-5-200409070-00101
Download citation file:
Published: Ann Intern Med. 2004;141(5):381-390.
Even with optimal pharmacotherapy, symptomatic heart failure is associated with substantial morbidity and mortality.
To determine the efficacy and safety of cardiac resynchronization therapy in adults with advanced systolic heart failure.
The Cochrane Central Register of Controlled Trials (2002, volume 4), MEDLINE (1980â€“2003), EMBASE (1980â€“2003), other electronic databases, and U.S. Food and Drug Administration reports. We contacted primary study authors and device manufacturers, and we hand searched bibliographies of relevant papers and conference proceedings.
Randomized, controlled clinical trials for efficacy and controlled trials plus prospective cohort studies for safety.
Two reviewers chose studies and extracted data independently; random-effects models were used for analyses.
Nine trials were included in the efficacy review (3216 patients). All trial participants had reduced ejection fraction and prolonged QRS duration, and 85% had New York Heart Association (NYHA) class III or IV symptoms. Cardiac resynchronization therapy improved ejection fraction (weighted mean difference, 0.035 [95% CI, 0.015 to 0.055]), quality of life (weighted mean reduction in score on the Minnesota Living with Heart Failure Questionnaire, 7.6 points [CI, 3.8 to 11.5 points]), and function (58% vs. 37% of patients improved by at least 1 NYHA class). Heart failure hospitalizations were reduced by 32% (relative risk [RR], 0.68 [CI, 0.41 to 1.12]), with benefits most marked in patients with NYHA class III or IV symptoms at baseline (RR, 0.65 [CI, 0.48 to 0.88]; number needed to treat for benefit [NNTB], 12). All-cause mortality was reduced by 21% (RR, 0.79 [CI, 0.66 to 0.96]; NNTB, 24), driven largely by reductions in death from progressive heart failure (RR, 0.60 [CI, 0.36 to 1.01]). Eighteen studies (total of 3701 patients with cardiac resynchronization devices) were included in the safety review. Implant success rate was 90% (CI, 89% to 91%), and 0.4% of patients died during implantation (CI, 0.2% to 0.7%). Over a median 6-month follow-up, leads dislodged in 9% of patients (CI, 7% to 10%) and mechanical malfunctions occurred in 7% (CI, 5% to 8%).
These trials enrolled only patients with heart failure with NYHA class III or IV symptoms despite medical therapy, a prolonged QRS duration, and reduced ejection fraction; in addition, experienced providers implanted the devices. Because all but one of these trials randomly assigned patients after device implantation, their results may overestimate the potential benefits of cardiac resynchronization. Finally, since few patients in these trials had bradyarrhythmias or atrial fibrillation, the role of cardiac resynchronization in such patients is uncertain.
In selected patients with heart failure, cardiac resynchronization therapy improves functional and hemodynamic status, reduces heart failure hospitalizations, and reduces all-cause mortality.
FDA = U.S. Food and Drug Administration.
Appendix Table 1.
Appendix Table 2.
Appendix Table 3.
Appendix Table 4.
Appendix Table 5.
Appendix Table 6.
Appendix Table 7.
Appendix Table 8.
Appendix Table 9.
Appendix Table 10.
Appendix Table 11.
Appendix Table 12.
Appendix Table 13.
Appendix Table 14.
Appendix Table 15.
Appendix Table 16.
Appendix Table 17.
CHF = congestive heart failure; COMPANION = Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure; CONTAK CD = Guidant CONTAK CD CRT-D System Trial; MIRACLE = Multicenter InSync Randomized Clinical Evaluation; MIRACLE-ICD = Multicenter InSync Randomized Clinical Evaluation ICD [implantable cardioverter-defibrillator]; MUSTIC-AF = Multisite Stimulation in Cardiomyopathies Atrial Fibrillation; MUSTIC-SR = Multisite Stimulation in Cardiomyopathies Sinus Rhythm; PATH-CHF = Pacing Therapies for Congestive Heart Failure; RR = relative risk.
CHF = congestive heart failure; CONTAK-CD = Guidant CONTAK CD CRT-D System Trial; MIRACLE = Multicenter InSync Randomized Clinical Evaluation; MIRACLE-ICD = Multicenter InSync Randomized Clinical Evaluation ICD [implantable cardioverter-defibrillator]; MUSTIC- AF = Multisite Stimulation in Cardiomyopathies Atrial Fibrillation; MUSTIC-SR = Multisite Stimulation in Cardiomyopathies Sinus Rhythm; RR = relative risk.
CHF = congestive heart failure; COMPANION = Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure; CONTAK- CD = Guidant CONTAK CD CRT-D System Trial; MIRACLE = Multicenter InSync Randomized Clinical Evaluation; MIRACLE-ICD = Multicenter InSync Randomized Clinical Evaluation ICD [implantable cardioverter-defibrillator]; MUSTIC-AF = Multisite Stimulation in Cardiomyopathies Atrial Fibrillation; MUSTIC-SR = Multisite Stimulation in Cardiomyopathies Sinus Rhythm; PATH-CHF = Pacing Therapies for Congestive Heart Failure.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Cardiology, Heart Failure.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only